ClinicalTrials.gg
RecruitingNCT06076538Updated Aug 4, 2026

PET/MR for Characterization of Renal Masses (RMs)

An observational study in Renal Tumor, Renal Cell Carcinoma and Renal Tumor, Benign, sponsored by University of Texas Southwestern Medical Center. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by University of Texas Southwestern Medical Center · Observational

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
97
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Carcinoma, Renal Cell by University of Texas Southwestern Medical Center — 5 open to participants now, 6 under way, none of them phase 3. Carcinoma, Renal Cell · University of Texas Southwestern Medical Center.

Started
2023
with 2 others
Observational
Only one
of the 10
Registered
9th of 10
by date

Among the 10 studies in Carcinoma, Renal Cell by University of Texas Southwestern Medical Center, this one is one of 3 that started in 2023, is the only observational one, and was the 9th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

5 of the 10 studies in Carcinoma, Renal Cell by University of Texas Southwestern Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Carcinoma, Renal Cell by University of Texas Southwestern Medical Center, or all of them as a file.
02

Study summary

The frequency of kidney tumors found incidentally on imaging studies performed for unrelated reasons continues to increase leading to more surgeries and ablations for the treatment of renal masses thought to be cancer. However, about 20% of these masses are not cancerous and do not require treatment. Many cancerous kidney tumors are indolent and can be followed safely with imaging (i.e., particularly tumors \<2 cm and in patients with limited life expectancy), while some tumors are both malignant and aggressive, with a higher potential to spread outside the kidney and require treatment.

The purpose of this observational study is to assess the ability of Fludeoxyglucose (18F) (FDG) PET/MR to distinguish different types of kidney tumors. The investigators hypothesize that PET/MR will better show differences between aggressive and both indolent and benign kidney masses compared to the currently used radiologic scans.

Participants will be selected from those who have been scheduled to receive a contrast-enhanced MRI for their regular care due to a suspicious kidney mass. Participants will have their MRI on a hybrid PET/MR scanner capable of obtaining both MRI and PET images. While they are receiving their standard of care MRI exam, patients will also receive a research FDG PET exam. Participants will have an IV placed for administration of the MRI contrast agent, just as they would if they were not taking part in the study. The same IV will be used to give the FDG radiopharmaceutical for the PET scan and furosemide (a diuretic), to help empty the bladder before the scan and help better see the kidneys on the scans. Both FDG and furosemide are FDA approved medications. Participants will have only one visit with the research team which will last \~2.5 hours and will include collection of the participant's regularly scheduled MRI.

If participants undergo surgery to remove the tumor, the study will collect samples of the removed tissue for research. If participants receive a biopsy of the tumor, the study may collect an additional sample of the tumor for research.

After the PET/MRI, participants will not have additional visits with the study team, but the study team may call every 6-12 months for up to 2 years to see how they are doing and ask about their health. The study team will review the medical record for any changes to their diagnosis, updates to their medical history, new scans ordered by their regular doctor, or recent lab or biopsy results.

Read the detailed description

Renal cell carcinoma (RCC) is most commonly diagnosed as an incidental small renal mass (SRM, ≤4cm [cT1a]). The incidence of RCC has markedly increased in the last few decades due to the widespread utilization of cross-sectional imaging. The increased detection of renal masses has resulted in an accompanying increase in the number of surgeries and ablations performed for a mass suspected of being a cancer. However, despite aggressive treatment of SRMs over the last few decades, there has not been a substantial decrease in kidney cancer-specific mortality suggesting an over-treatment effect - i.e., many patients may not benefit from extirpative or ablative treatment. Furthermore, approximately 20% of small (≤4 cm) solid renal masses are benign neoplasms, mostly oncocytoma and angiomyolipoma. Benign masses generally do no harm and can be ignored or followed up as they do not limit a patient's lifespan. Even when malignant, small solid masses are frequently indolent with low rates of local disease progression or metastasis. The proportion of benign diagnoses and indolent RCCs is higher among solid masses smaller than 2 cm. Although percutaneous renal mass biopsy can offer a definitive diagnosis, it is not feasible in every patient, and carries a high non-diagnostic rate (14-19%), has low negative predictive value (63%) and underestimates tumor grade. For these reasons, combined with a desire to identify aggressive renal masses with increased risk of progression or metastasis promptly and decrease patient morbidity and health-care costs related to unnecessary treatments, there is a need for developing imaging techniques that better characterize renal masses. In addition to differentiating benign from malignant disease, distinction between indolent malignant renal masses from aggressive neoplasms is important for decision making, with the later typically requiring prompt intervention. In contrast, active surveillance may be favored for patients with indolent malignancies, particularly for those with competing comorbidities and limited life expectancy. Unfortunately, the lack of reliable predictors of oncologic behavior have also limited the wide clinical adoption of active surveillance as a management strategy. Aggressive renal masses are classified by the presence of any high grade (HG, International Society of Urogenital Pathology (ISUP) grade 3 or 4 out of 4) features on histology or the presence of sarcomatoid and rhabdoid features, coagulative necrosis.

Alternatively, a diagnosis of the histologic subtype of RCC may assist in management decisions. For example, clear cell renal cell carcinoma (ccRCC) is the most common histology and metastasizing tumor. The clear cell likelihood score (ccLS) is a 5-tier system developed at the University of Texas Southwestern Medical Center (UTSW) to predict the likelihood of a solid renal mass to represent a clear cell renal cell carcinoma. In a multicenter, retrospective study, the reported pooled sensitivity, specificity, and positive predictive value for ccRCCs using a ccLS of 4 or 5 were 75% (95% CI: 68, 81), 78% (95% CI: 72, 84), and 76% (95 CI: 69, 81), respectively. The negative predictive value for a ccLS of 1 or 2 was 88% (95% CI: 81,93).

Patients referred for MRI of an indeterminate renal mass will be eligible for this study. PET/MRI in this study will be performed as a replacement of the standard-of-care MRI examination. Thus, the PET component of the PET/MR examination is a research procedure. Patients will be screened for any contraindication of MRI (e.g., unsafe indwelling device) as it is routinely done in the Department of Radiology for clinical MRI examinations. Patients will be administered with 12 mCi of FDG I.V, which is consistent with the FDG radiation dose patients receive for FDG PET/CT examinations performed as standard of care. Patients will receive 20 mg of furosemide 60 min after administration of FDG. The patient will be asked to empty their bladder as much as needed for the following 60 min. The patient will then be placed on the PET/MRI table 60 min after administration of FDG for a 10 min quick PET/MR acquisition the abdomen. The patient will be removed from the scanner and asked to empty their bladder as needed. The patient will be placed on the MRI scanner again 120 min after the administration of FDG to complete their standard of care MRI. A gadolinium-enhanced MRI of the kidneys will be obtained using the standard clinical protocol for MRI of renal masses at UTSW. An extracellular gadolinium-based contrast agent will be administered during the MRI and is not part of the study procedures. PET data of the kidneys will be acquired simultaneously during the MRI examination as part of the study procedures. UTSW standard operating procedures will be followed with regards to fasting and blood glucose measurements for patients undergoing FDG PET imaging in this study. PET images will be coregistered to MRI data and mean and maximum standardized uptake value in the renal mass will be calculated. MRI images will be interpreted using the standard clinical report and a ccLS will be provided. For patients undergoing standard of care biopsy, an extra core will be obtained for future research from participants who opt-in to have extra core collected when they sign informed consent form. If the renal mass is resected surgically, a piece of discarded tissue will be collected for similar correlative studies. The extra core or the discarded tissue will be used for histology and metabolomics analysis to understand the correlation of FDG uptake and tumor metabolism.

03

Conditions studied

  • Renal Tumor
  • Renal Cell Carcinoma
  • Renal Tumor, Benign

Keywords

  • Renal Mass
  • Renal Cell Carcinoma
  • PET/MR
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Eligible patients will complete their clinically indicated MRI with the addition of the research infusion of the FDA approved FDG radiotracer and PET portion of the scan. Eligibility waivers are not permitted. Subjects must meet all of the inclusion and exclusion criteria to be registered to the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with known solid (>25% total volume enhances) renal mass
  • Renal mass size measuring >2 to ≤7 cm
  • Age >18 years
  • Ability to understand and the willingness to sign a written .

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Prior percutaneous of the renal mass
  • Prior treatment of the renal mass
  • Prior hemorrhage in the renal mass
  • to MRI or PET
  • Renal mass not eligible for ccLS based on prior imaging (i.e., containing macroscopic fat [classic angiomyolipoma] or enhancing less than 25% of its volume [considered a cystic renal mass])
  • Genetic syndrome predisposing to renal masses (e.g., VHL, BHD, TSC, etc.);
  • More than 3 renal masses at time of initial diagnosis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
97 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patient diagnosed with incidental solid renal mass

    All patients at our institution who are diagnosed with indeterminate solid SRM and without prior treatment for the tumor, renal biopsy or contraindication to PET/MRI can be included in the study. This will be a prospective, non-randomized, non-blinded observational study. Patients will then be managed following the standard of care.

    Diagnostic Test: 2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging

Interventions

  • Diagnostic test2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging

    PET/MR scan utilizing FDG Radiopharmaceutical

    Also known as: FDG PET/MR

06

What researchers measure

Primary outcomes

  1. Prediction of SRM aggressiveness with PET

    To test the difference in mean SUVmax between HG malignant renal masses and other (LG malignancies and benign) renal masses.

    Time frame: Baseline

Secondary outcomes

  1. Prediction of SRM aggressiveness with the metabolic clear cell likelihood score (m-ccLS)

    To determine the diagnostic performance of combining SUVmax and clear cell likelihood score (ccLS; ranging from 1 (very unlikely) to 5 (very likely)) in detecting HG SRM size \>2 to ≤7 cm and compare to that of ccLS alone.

    Time frame: Baseline

  2. Prediction of aggressive clear cell histology with the metabolic clear cell likelihood score (m-ccLS)

    To determine the diagnostic performance of combining SUVmax and clear cell likelihood score (ccLS; ranging from 1 (very unlikely) to 5 (very likely)) in detecting HG ccRCC from all solid SRM size \>2 to ≤7 cm and compare to that of ccLS alone.

    Time frame: Baseline

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual Participant Data will not be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Jun 2028, 58 months after the start.

Of 97 non-industry observational studies under Carcinoma, Renal Cell, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 241. This study's planned 58 months is above that.

Counting every sponsor, half of 139 studies reached it within 50 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2023
First posted
Oct 11, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Jun 1, 2028
CompletionEst.
Jun 1, 2028
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06076538
Collaborators
Radiological Society of North America
Responsible party
Robert Sibley (Assistant Professor, Radiology, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Oct 11, 2023
Start date
Aug 1, 2023
Primary completion
Jun 1, 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Aug 4, 2026

Study contacts

UTSW Radiology Clinical Research Office
Contact
RCRO@utsouthwestern.edu
214-645-1568
Robert C Sibley, MD
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion